Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sipuleucel-T - Dendreon Corporation

Drug Profile

Sipuleucel-T - Dendreon Corporation

Alternative Names: APC-8015; APC8015F; Autologous PAP-loaded dendritic cell vaccine - Dendreon; Prostate cancer vaccine (APC-8015) - Dendreon; Prostate-cancer-vaccine-APC-8015-Dendreon; Provenge

Latest Information Update: 07 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines; Dendritic cell vaccines; T lymphocyte cell therapies; Tissue extracts
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 31 Oct 2019 Dendreon Pharmaceuticals completes enrolment in its phase III ProVent trial for Prostate cancer in USA (IV, Infusion) (NCT03686683)
  • 04 Jul 2019 Sipuleucel-T is not yet available for Prostate cancer (Hormone refractory, Metastatic disease) in Iceland, Liechtenstein, Norway
  • 12 Dec 2018 University of Minnesota completes a phase II trial in Prostate cancer (Metastatic disease, Hormone refractory) in USA (PO) (NCT01560923)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top